First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens

Моисеев, И. С.; Barabanshikova, Maria V.; Dotsenko, Anna A.; Smirnova, Anna G.; Vlasova, Yulia; Morozova, Еlena V.; Bondarenko, Sergey N.

doi:10.1038/s41409-022-01879-0

Bone Marrow Transplant

2022

DOI: 10.1038/s41409-022-01879-0

|View full text |Cite

First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens

И. С. Моисеев

Maria V. Barabanshikova

Anna A. Dotsenko

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 47 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease

Kujawska,

Zeiser,

Gil

2024

Ann Hematol

View full text Add to dashboard Cite

Acute Graft versus Host Disease (aGvHD) is a common immunological complication occurring in patients undergoing allogeneic hematopoietic stem cell transplantation (allo-HSCT). Moreover, aGvHD is associated with a higher risk of infections and metabolic complications, affecting non-relapse mortality. Progress in transplantation has changed the prophylactic and therapeutic strategies of aGvHD and improved patient outcomes. The standard first-line therapy remains steroids, with a response rate of about 50%. The Janus Kinase 2 (JAK2) inhibitor, ruxolitinib, is an effective second-line therapy. The management of patients who developed a disease that is refractory to steroids and ruxolitinib, especially in the severe gastrointestinal forms of aGvHD, is not validated and remains an unmet medical need. In the article, we present the current clinical practice, as well as the latest advances targeting pathophysiological pathways of GvHD and gut microbiota, which may be a potential future of aGvHD therapy.

show abstract

Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease

Kujawska,

Zeiser,

Gil

2024

Ann Hematol

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

First-line steroid-free systemic treatment of acute and chronic graft-versus-host disease after novel prophylaxis regimens

Cited by 1 publication

References 47 publications

Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease

Recent advances in acute gastrointestinal graft versus host disease (aGvHD): aspects of steroid-resistant disease

Contact Info

Product

Resources

About